Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial

Veradermics, Inc

VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)
79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo
No treatment-related serious adverse events or cardiac adverse events of special interest observed
Statistically significant separation from placebo observed as early as Month 2

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.